Everything below concerns human growth hormone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
=== Immunodeficiency === As the thymus is where T cells develop, congenital problems with the development of the thymus can lead to immunodeficiency, whether because of a problem with the development of the thymus gland or a problem specific to thymocyte development. Immunodeficiency can be profound. Loss of the thymus at an early age through genetic mutation (as in DiGeorge syndrome, CHARGE syndrome, or a very rare "nude" thymus causing absence of hair and the thymus) results in severe immunodeficiency and subsequent high susceptibility to infection by viruses, protozoa, and fungi. Nude mice with the very rare "nude" deficiency due to FOXN1 mutation are a strain of research mice used as a model of T cell deficiency. The most common congenital cause of thymus-related immune deficiency results from the deletion of the 22nd chromosome, called DiGeorge syndrome. This results in a failure of development of the third and fourth pharyngeal pouches, failing development of the thymus, and variable other associated problems, such as congenital heart disease, and abnormalities of mouth (such as cleft palate and cleft lip), failure of development of the parathyroid glands, and the presence of a fistula between the trachea and the oesophagus. Very low numbers of circulating T cells are seen. The condition is diagnosed by fluorescent in situ hybridization and treated with thymus transplantation. Severe combined immunodeficiency (SCID) is a group of rare congenital genetic diseases that can result in combined T, B, and NK cell deficiencies.
==== Mid-20th century (1945–1985) ==== After the end of World War II, Britain implemented a National Health Service. Douglas Gairdner's 1949 article "The Fate of the Foreskin" argued that the evidence showed that the risks outweighed the benefits, leading to a significant reduction in circumcision incidence within the United Kingdom. In contrast to Gairdner, American pediatrician Benjamin Spock argued in favor of circumcision in his popular The Common Sense Book of Baby and Child Care which led to rates in the United States significantly rising. In the 1970s, national medical associations in Australia and Canada issued recommendations against routine infant circumcision, leading to drops in the rates of both of those countries. The United States made similar statements in the 1970s but stopped short of recommending against it. During the same period, South Korea underwent one of the most rapid and distinctive shifts in circumcision practice recorded anywhere in the world. Throughout their long history, Koreans did not circumcise males until 1945, when Korea gained its independence after 36 years of Japanese occupation. Independence brought trusteeship by the American military in the southern half of the country, and 1950 can be safely regarded as the year when widescale circumcision started in South Korea.
The cars were cleaned with hot water or steam. Depending on the cargo, the cars might have undergone four hours of "pre-cooling" before loading, which entailed blowing in cold air through one ice hatch and allowing the warmer air to be expelled through the other hatches. The practice, dating back almost to the refrigerator car's inception, saved ice and resulted in fresher cargo. The cars' ice bunkers were filled, either manually from an icing dock, via mechanical loading equipment, or (in locations where demand for ice was sporadic) using specially designed field icing cars. The cars were delivered to the shipper for loading, and the ice was topped off. Depending on the cargo and destination, the cars may have been fumigated. The train would depart for the eastern markets. The cars were re-iced in transit approximately once a day. Upon reaching their destination, the cars were unloaded. If in demand, the cars would be returned empty to their point of origin. If not in demand, the cars would be cleaned and possibly used for a dry shipment.
=== Magnetic substrates === In 2010, researchers magnetized graphene by producing it via CVD on the Ni(111) substrate and then in 2014 by placing it on an atomically smooth layer of magnetic yttrium iron garnet, maintaining graphene's electronic properties unaffected. Previous methods involved doping graphene with other substances. The dopant's presence negatively affected its electronic properties.
Sources: en.wikipedia.org
=== Dulling of a chain === Chains will naturally dull over time with use. The friction cause by cutting wood gradually wears the chain's teeth down. However, the technique of use can also contribute to a chain dulling quickly. Cutting at too sharp an angle, cutting into dirt, and cutting frozen wood can prematurely dull your chain.
While majorities might signal their support for certain ideals such as "environmental consciousness" to pollsters, actual purchases do not reflect their stated views, as can be seen from their high demand for cheap but not durable clothing ("fast fashion"), or preference for rapid delivery. Overall, although more than half say they sought environmentally friendly products, only 38% are willing to pay extra for them. While majorities of older cohorts prefer American products, Generation Z is mixed on whether or not to buy goods made in China.Nostalgia is a major theme of the behavior of consumers from Generation Z. For example, 2000s vintage electronics and fashion are back in vogue by the early 2020s. Youths who came of age during the 2010s and 2020s feel nostalgic about "simpler" eras of history they have never experienced due to the uncertainties and stress of modern life, with student loan debts and the threat of terrorism being the top concerns. Despite having the reputation for "killing" many things valued by older generations, Millennials and Generation Z are nostalgically preserving Polaroid cameras, vinyl records, needlepoint, and home gardening, to name just some. In fact, while "dumb phones" (or feature phones rather than smartphones) are on the decline around the world, in the U.S., their sales are growing among Generation Z. According to a 2019 YouGov poll, 31% of the U.S. population is willing to pay for music on vinyl, including 26% of Generation Z.
== Notable people == The teaching of medicine at the University of Cambridge dates back to 1540 when Henry VIII endowed the University’s first Professorship of Physic, Dr John Blyth. In 1842, George Paget, the famous physician, into his third year at Addenbrooke’s Hospital, pioneered bedside examinations.
== American Society for Mass Spectrometry == The major awards from the American Society for Mass Spectrometry are John B. Fenn Award for a Distinguished Contribution in Mass Spectrometry, Biemann Medal, Fellows of ASMS, Research Award, Research at Primarily Undergraduate Institutions (PUIs) Award, Al Yergey Mass Spectrometry Scientist Award, Ron Hites Award, and Diversity, Equity, Inclusion, and Accessibility Mentorship Award. A number of notable women mass spectrometrists served as presidents of the American Society for Mass Spectrometry.
=== Professional directories === The IIR publishes two professional directories: a Laboratory Directory, which lists more than 300 laboratories in 55 countries; an Expertise Directory, which lists over 300 international experts in the refrigeration sector.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.